Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026

• Vertex and Medtronic could spot beardown momentum this year, portion Pfizer is inactive facing challenges.

• Regardless of what happens successful 2026, though, Vertex and Medtronic person charismatic prospects.

• 10 stocks we similar amended than Vertex Pharmaceuticals ›

Pfizer's (NYSE: PFE) shares person been southbound for the past 3 years. And unluckily for the company, it doesn't look similar things volition amended importantly successful 2026. The pharmaceutical giant's caller guidance for the fiscal play that has conscionable started doesn't look promising, and it is inactive facing important patent cliffs implicit the adjacent 2 years, including for Eliquis, an anticoagulant that is 1 of its best-selling products. What's worse, Pfizer has yet to nutrient results from objective trials for candidates that could regenerate Eliquis arsenic good arsenic its dwindling COVID-19 franchise.

While I judge Pfizer volition rebound eventually, it volition instrumentality immoderate clip to bash so, and it whitethorn not hap successful 2026. In the meantime, different healthcare leaders could execute importantly amended this twelvemonth and surpass Pfizer's marketplace value, including Vertex Pharmaceuticals (NASDAQ: VRTX) and Medtronic (NYSE: MDT). Here's the rundown.

Vertex Pharmaceuticals experienced important volatility successful 2025 arsenic it encountered respective roadblocks. Financial results weren't arsenic beardown arsenic expected successful immoderate quarters, and the institution abandoned the improvement of a medicine for benignant 1 diabetes (T1D) portion encountering objective roadblocks with different candidates.

However, 2026 promises to beryllium a overmuch amended twelvemonth for the biotech. Vertex's results should improve. The institution remains the lone 1 successful the satellite that makes medicines for the underlying causes of cystic fibrosis (CF), a uncommon lung disease. There are inactive plentifulness of patients to dainty for this condition. Also, Vertex should spot newer approvals, peculiarly Journavx, a medicine for acute pain, marque advancement this year. Journavx became the archetypal oral, non-opioid symptom inhibitor to gain support past year.

Since opioid-based medications travel with perchance terrible broadside effects, we should spot Journavx pull a important fig of patients.

Elsewhere, we should besides spot objective and regulatory advancement for the drugmaker. On the regulatory side, Vertex Pharmaceuticals expects to taxable applications to the U.S. Food and Drug Administration (FDA) for zimislecel, an investigational therapy for T1D that is performing good successful objective trials. It is successfully restoring patients' quality to nutrient their ain insulin oregon astatine slightest decreasing insulin dependence.